Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19…
Results from the DESTINY-Breast12 Phase IIIb/IV trial reveal that Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, including those with brain…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first subcutaneous (SC) PD-(L)1 inhibitor for cancer…
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved EBGLYSS™ (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis (eczema) in adults…
Jackson Egen discovered the significance of fundamental lab research during his graduate studies at UC Berkeley in the 1990s, working under the guidance of esteemed immunologist James Allison. “Jim emphasized…
Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a U.S.-based biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT), and Orano Med, a French…
Pfizer Inc. (NYSE: PFE) continues to highlight groundbreaking research and next-generation therapies from its comprehensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, held from September…
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that BOTOX® Cosmetic (onabotulinumtoxinA) is now available in China for the treatment of masseter muscle prominence (MMP). The masseter muscle,…
Eli Lilly and Company (NYSE: LLY) today released detailed findings from the QWINT-5 phase 3 trial, which compared once-weekly insulin efsitora alfa (efsitora) to daily insulin degludec in adults with…
Oisín Biotechnologies, a privately held company dedicated to addressing age-related diseases, has announced the publication of preclinical data from its follistatin (FST) gene therapy program. The findings, detailed in the…
Novotech, a leading global full-service Contract Research Organization (CRO), has been honored with the 2024 Global Company of the Year Award by Frost & Sullivan. This prestigious accolade highlights Novotech’s…
Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and other serious conditions, has announced the launch of an underwritten public offering of…